Caris Life Sciences, Inc.
CAI
$18.22
-$0.25-1.35%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | ||
|---|---|---|---|---|---|
| Net Income | 75.85% | -- | -- | -- | |
| Total Depreciation and Amortization | -53.76% | -- | -- | -- | |
| Total Amortization of Deferred Charges | 81.00% | -- | -- | -- | |
| Total Other Non-Cash Items | 1,421.67% | -- | -- | -- | |
| Change in Net Operating Assets | -13.97% | -- | -- | -- | |
| Cash from Operations | 133.91% | -- | -- | -- | |
| Capital Expenditure | -92.56% | -- | -- | -- | |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | |
| Cash Acquisitions | -- | -- | -- | -- | |
| Divestitures | -- | -- | -- | -- | |
| Other Investing Activities | -- | -- | -- | -- | |
| Cash from Investing | -130.72% | -- | -- | -- | |
| Total Debt Issued | -86.07% | -- | -- | -- | |
| Total Debt Repaid | 32.48% | -- | -- | -- | |
| Issuance of Common Stock | 34,938.95% | -- | -- | -- | |
| Repurchase of Common Stock | -- | -- | -- | -- | |
| Issuance of Preferred Stock | -- | -- | -- | -- | |
| Repurchase of Preferred Stock | -- | -- | -- | -- | |
| Total Dividends Paid | -- | -- | -- | -- | |
| Other Financing Activities | -35.98% | -- | -- | -- | |
| Cash from Financing | 232.01% | -- | -- | -- | |
| Foreign Exchange rate Adjustments | 3,350.00% | -- | -- | -- | |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | |
| Net Change in Cash | 9,026.22% | -- | -- | -- | |